Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · HERON THERAPEUTICS, INC. /DE/ (HRTX)

Heron Therapeutics Q3 revenue falls 7.8% to $35.3 million; agrees to asset sale

Mixed Impact 5 of 5 m&a

Heron Therapeutics reported third-quarter 2026 net revenue of $35.3 million, down 7.8% from $38.2 million a year earlier, while its net loss narrowed to $5.0 million from $17.5 million. The same day, Heron agreed to sell substantially all of its assets to CorMedix Therapeutics, a deal that requires Heron stockholder approval, and the company is not providing 2026 financial guidance.

Key points

  • Q3 2026 net revenue was $35.3 million, compared with $38.2 million in Q3 2025 and $37.7 million in Q2 2026.
  • Q3 2026 net loss was $5.0 million, compared with $17.5 million in Q3 2025.
  • CorMedix Therapeutics will acquire substantially all of Heron's assets under a definitive asset purchase agreement, subject to Heron stockholder approval and other closing conditions.
  • Heron withdrew its full-year 2026 guidance in August 2026 and is not providing guidance at this time; cash and short-term investments were $23.4 million at September 30, 2026.

The filing

CompanyHERON THERAPEUTICS, INC. /DE/ (HRTX)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:15 AM ET
Accession number0001193125-26-452721

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:31 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.